Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
Evolus, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Positioning Delivered 12% full-year revenue growth despite 2025 being only the third time in 25 years that U.S. injectable volumes declined. Attributed Jeuveau's 14% market share capture to a 'beauty-first' strategy that aligns with cash-pay aesthetic practices rather than reimbursement models. Successfully piloted a new portfolio growth rebate program designed to incentivize accounts to consolidate their toxin and filler spend with Evolus. Expanded the Evolysse HA filler footprint to over 3,000 purchasing accounts, leveraging Cold-X Technology to meet consumer demand for natural-looking results. Executed a structural expense reset in mid-2025 to align the organization for durable, profitable growth and meaningful operating leverage. International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and approaching double-digit share in the U.K. Mai
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.MarketBeat
- Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]Seeking Alpha
- Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 3/3/26 - Beat
EOLS
Sec Filings
- 3/3/26 - Form S-8
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- EOLS's page on the SEC website